Daisuke Morichika
Okayama University
Internal medicineRetinoid X receptorEndocrinologyPulmonary complianceSurgeryPathologyOncologyInterleukin 23CardiologyReceptorImmunologyRetinoidLung cancerPancreatic elastaseChemotherapyCOPDExacerbationLungBronchoalveolar lavageCisplatinBronchoscopyEpidermal growth factor receptorElastaseLow volumeCisplatin based chemotherapyPartial agonistNuclear receptorMedicineImmune systemNeuropeptide Y receptor
20Publications
8H-index
111Citations
Publications 20
Newest
#1Naohiro OdaH-Index: 8
Last. Ichiro TakataH-Index: 15
view all 8 authors...
COVID-19 in cancer patients on immunosuppressive agents for the treatment of immune-related adverse events of immune checkpoint inhibitors can rapidly deteriorate. The combination therapy with methylprednisolone, baricitinib, and remdesivir may be effective for critical COVID-19, and further clinical trials are warranted.
Source
#1Daisuke Morichika (Okayama University)H-Index: 8
#2Akihiko Taniguchi (Okayama University)H-Index: 10
Last. Masayuki Hanaoka (Shinshu University)H-Index: 28
view all 15 authors...
Background IL-33, which is known to induce type 2 immune responses via group 2 innate lymphoid cells, has been reported to contribute to neutrophilic airway inflammation in chronic obstructive pulmonary disease. However, its role in the pathogenesis of emphysema remains unclear. Methods We determined the role of interleukin (IL)-33 in the development of emphysema using porcine pancreas elastase (PPE) and cigarette smoke extract (CSE) in mice. First, IL-33-/- mice and wild-type (WT) mice were giv...
Source
#1Kiichiro Ninomiya (Okayama University)H-Index: 11
#2Tae HataH-Index: 1
Last. M. TabataH-Index: 1
view all 128 authors...
Background Human epidermal growth factor 2 (HER2) is a potential driver oncogene. Although HER2-targeted precision therapy has been tested in non-small cell lung cancer (NSCLC), the demographic characteristics of HER2-positive NSCLC have not been systematically defined. Methods Patients with pathologically confirmed stage IIIB/IV or recurrent NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, were prospectively registered. HER2 immunohistochemistry (IHC) and fluorescence in sit...
11 CitationsSource
#1Naohiro Oda (Okayama University)H-Index: 8
#2X. Nobuaki Miyahara (RMIT: RMIT University)H-Index: 1
Last. Yoshinobu Maeda (Okayama University)H-Index: 29
view all 11 authors...
Neuropeptide Y (NPY) is a neurotransmitter that is widely expressed in the brain and peripheral nervous system. Various immune cells express the NPY Y1 receptor. NPY modulates these cells via its Y...
7 CitationsSource
#1Akihiko Taniguchi (Okayama University)H-Index: 10
#2Naohiro Oda (Okayama University)H-Index: 8
Last. Nobuaki Miyahara (Okayama University)H-Index: 33
view all 10 authors...
Source
#1Satoru Senoo (Okayama University)H-Index: 5
#2Akihiko Taniguchi (Okayama University)H-Index: 10
Last. Nobuaki Miyahara (RMIT: RMIT University)H-Index: 33
view all 10 authors...
Source
#1Daisuke Morichika (Okayama University)H-Index: 8
#2Nobuaki Miyahara (Okayama University)H-Index: 33
Last. Arihiko Kanehiro (Okayama University)H-Index: 25
view all 12 authors...
Retinoid X receptors (RXRs) are members of the nuclear receptor (NR) superfamily that mediate signalling by 9-cis retinoic acid, a vitamin A derivative. RXRs play key roles not only as homodimers but also as heterodimeric partners, e.g., for retinoic acid receptors, vitamin D receptors, and peroxisome proliferator-activated receptors. The NR family may also play important roles in the development of emphysema. However, the role of RXRs in the pathogenesis of emphysema is not well defined. We dev...
12 CitationsSource
#1Naohiro Oda (Okayama University)H-Index: 8
#2Nobuaki Miyahara (RMIT: RMIT University)H-Index: 33
Last. Arihiko Kanehiro (Okayama University)H-Index: 25
view all 10 authors...
11 CitationsSource
#1Akihiko TaniguchiH-Index: 10
#2Nobuaki Miyahara (RMIT: RMIT University)H-Index: 33
Last. Katsuyuki KiuraH-Index: 68
view all 12 authors...
Although recent retrospective studies suggested that the use of β-blockers appears to help improve the mortality rate and decrease the rate of exacerbation in chronic obstructive pulmonary disease (COPD) patients with heart failure, the effects of β-blockers on COPD patients without heart failure have not been established. Based on previous reports, we have launched a multicenter, prospective, single-arm phase II study to evaluate the preventive effect of the cardioselective β-blocker bisoprolol...
2 CitationsSource
#1Naohiro Oda (Okayama University)H-Index: 8
#2Nobuaki Miyahara (Okayama University)H-Index: 33
Last. Katsuyuki KiuraH-Index: 68
view all 12 authors...
BACKGROUND: Some recent studies have suggested that beta-blocker use in patients with chronic obstructive pulmonary disease (COPD) is associated with a reduction in the frequency of acute exacerbations. However, the long-term effects of beta-blocker use on lung function of COPD patients have hardly been evaluated. PATIENTS AND METHODS: We retrospectively reviewed 31 Japanese COPD patients taking beta-blockers for >1 year and 72 patients not taking them. The association between beta-blocker use a...
9 CitationsSource